Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
Grace Therapeutics announced its financial results for Q1 2027, highlighting progress on resubmitting the NDA for GTx-104, a novel IV formulation of nimodipine for aneurysmal subarachnoid hemorrhage (aSAH). The FDA's Complete Response Letter identified no clinical deficiencies but cited manufacturing-related issues, prompting a dual-source manufact…